Medication info

Samsung Linagliptin Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Bright orange oval film-coated tablet
Packaging
60 tablets/PTP[(10 tablets/PTP x 6)]
Approval status
Expired

MFDS item code 201907496 · Approved 2019.10.28

This product's status changed to Expired on 2024.10.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in adult type 2 diabetes patients
View approved original text

This medication is used alongside diet and exercise to help control blood sugar in patients with adult type 2 diabetes. It is administered in cases where patients have not received prior diabetes medication treatment or have difficulty controlling blood sugar with monotherapy. It is also prescribed for those who have insufficient blood sugar control with metformin monotherapy. Additionally, this medication is used to improve blood sugar control when replacing a combination of linagliptin and metformin or in cases where maximum doses of metformin along with sulfonylureas or empagliflozin have proven inadequate. For individuals who find it difficult to control using insulin and metformin combinations, this medication provides a treatment method used alongside insulin. In summary, this medication is utilized to improve treatment for adult type 2 diabetes patients who encounter difficulties with blood sugar control in various situations.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication has been reported to cause rare but serious side effects, such as lactic acidosis. Lactic acidosis is a condition where excessive lactate builds up in the body, causing increased acidity, which can be life-threatening without proper treatment. This medication should not be used in certain patients. For instance, it should not be used in patients who have allergies to its ingredients or in those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, diabetic coma, severe renal impairment, acute infections or dehydration affecting renal function, patients with severely impaired liver function, individuals with acute alcohol intoxication or alcohol dependence, patients with very poor nutritional status, acute heart failure patients, pregnant or nursing women, and patients with a history of myocardial infarction. When administering this medication, care must be taken to avoid the risk of hypoglycemia. Particularly when using this medication with sulfonylureas or insulin, hypoglycemic symptoms may occur, so dosage adjustments of other medications may be necessary. To reduce the risk of lactic acidosis, blood sugar control should be carefully managed, avoid prolonged fasting or excessive alcohol consumption, and exercise extra caution when liver or heart function is impaired. If symptoms like abdominal pain, muscle pain, weakness, or respiratory distress occur, immediate consultation with a doctor is required. Renal function is critical for the excretion of this medication, thus regular kidney function tests must be conducted before and during treatment, and the medication should be discontinued if renal function falls below a certain standard. Patients with diminished cardiac function should be closely monitored when using this medication, and it should be temporarily discontinued prior to examinations involving radiographic iodine contrast agents. Patients undergoing surgery should also stop taking this medication for a period before and after the procedure. This medication can cause rare skin conditions such as acute pancreatitis or bullous pemphigoid, so if severe abdominal pain or blisters appear on the skin, medical personnel should be notified immediately. Long-term use may lead to vitamin B12 deficiency, so if anemia or neurological symptoms develop, vitamin B12 levels should be checked, and supplementation, if necessary, should be administered. This medication can interact with other drugs, so if any other medications are being taken, it is essential to inform a doctor or pharmacist. Special care should be taken when using it with medications that may affect renal function or blood-sugar-lowering medications. Women who are pregnant or planning to become pregnant should avoid this medication, and nursing mothers should also refrain from using it. The safety and efficacy in children and adolescents have not been established; therefore, use in this age group is not recommended. Elderly patients may frequently have declining renal function, so renal function should be regularly monitored and the dosage adjusted accordingly when using this medication. There have been no studies conducted on the effects on driving or operating machinery, so caution is advisable while taking this medication. In the case of overdose, there is a risk of lactic acidosis, and one should seek immediate hospital treatment as hemodialysis is an effective treatment method. This medication should be stored out of reach of children, in a dry place, and it is advisable not to transfer it to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 176 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular-like pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbance
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus damage
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pruritus
  • insomnia
  • depression
  • hypertension
  • erectile dysfunction
  • goiter
  • anxiety
  • insomnia
  • depression
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • upper abdominal pain
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • headache
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • dysphonia
  • dyspnea
  • nasal hemorrhage
  • hearing loss
  • benign prostatic hyperplasia
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • skin lesions
  • dermatitis
  • anxiety
  • affective disorder
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • dizziness
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • diabetic neuropathy
  • headache
  • subdural effusion
  • angina
  • acute myocardial infarction
  • unstable angina
  • corneal abrasion
  • falls
  • ligament sprain
  • upper limb fracture
  • dysphonia
  • dyspnea
  • nasal hemorrhage
  • vocal cord polyp
  • dizziness
  • dyslipidemia
  • hypercholesterolemia
  • myelodysplastic syndrome
  • papilloma
  • thyroid nodule
  • vitreous hemorrhage
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and humidity, thus it must be stored in a tightly sealed container. A storage location maintaining room temperature between 1°C and 30°C is suitable.

Appearance and packaging

Appearance

Bright orange oval film-coated tablet

Package unit

60 tablets/PTP[(10 tablets/PTP x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.